| Patient demographics | |
| Age, median (IQR) | 69.0 (63.0–75.0) | Gender, n (%), M/F | 26/19 (57.8/42.2) | BMI, median (IQR), kg/m2 | 26.8 (22.5–28.7) | Smoking status, n (%), 1/2/3 | 9/9/27 (20.0/20.0/40.0) | ASA, n (%), 1/2/3/4 | 4/25/14/2 (8.9/55.6/31.1/4.4) | Comorbidity, n (%), 0/1/2/≥3 | 10/21/10/4 (22.2/46.7/22.2/8.9) | Medications, n, 1/2/3/4 | 21/9/11/7 | CR-POSSUM (predicted mortality [%]), median (IQR) | 2.5 (1.3–3.9) |
| Presentation | |
| Presentation, n (%), 1/2 | 39/6 (86.7/13.3) | Cancer location, n (%), 1/2 | 27/18 (60.0/40.0) |
| Tumour characteristics | |
| Neoadjuvant therapy, n (%), y | 11 (24.4) | T-Stage, n (%), 0/1/2/3/4 | 2/2/9/22/9 (4.5/4.5/20.5/50.0/20.5) | N-Stage, n (%), 0/1/2 | 32/8/4 (72.7/18.2/9.1) | M-Stage, n (%), 0/1 | 42/2 (95.5/4.5) | Dukes’ stage, n (%), A/B/C/D | 9/22/11/2 (20.5/50.0/25.0/4.5) | Differentiation, n (%), 1/2 | 39/5 (88.6/11.4) | Extramural venous invasion, n (%), y | 14 (32.6) |
|
|